Restoration of erythropoiesis by rituximab in an adult patient with primary acquired pure red cell aplasia refractory to conventional treatment [3]

British Journal of Haematology

Volumn 116, Issue 3, 2002, Pages 727-728

  Auner, Holger W ^a   Wölfler, Albert ^a   Beham Schmid, Christine ^a   Strunk, Dirk ^a   Linkesch, Werner ^a   Sill, Heinz ^a  

^a Department of Medicine and Institute of Pathology ^*  (Austria)

Author keywords

CD20; Pure red cell aplasia; Rituximab

Indexed keywords

CYCLOSPORIN A; ERYTHROPOIETIN; PREDNISONE; RITUXIMAB; THYMOCYTE ANTIBODY;

AGED; BONE MARROW BIOPSY; CASE REPORT; CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; DISEASE COURSE; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MALE; PRIORITY JOURNAL; PURE RED CELL ANEMIA; RETICULOCYTE COUNT; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; BONE MARROW; ERYTHROPOIESIS; HUMANS; MALE; RED-CELL APLASIA, PURE;

EID: 0036177513     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.3317_3.x     Document Type: Letter

References (4)

1. The pathophysiology of pure red cell aplasia: Implications for therapy
2. Pure red cell aplasia
3. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four dose treatment program
4. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia